Directorio de personas
Silvia Peralta Moncusi

Silvia Peralta Moncusi

Grado: Diplomado/a


Publicaciones

  • Sancho--Saldaña, A; Gil-Sánchez, A; González-Mingot, C; Peralta, S; Solana, MJ; Torres, P; Juanes, A; Quibus, L; Ruiz, E; Sanpedro, E; Quirant-Sánchez, B; Martínez-Cáceres, E; Tello, CR; Presas-Rodríguez, S; Rubio, SG; Baron, BP; Ramio-Torrenta, L; Sotoca, J; González-Suarez, I; Eichau, S; Prieto-Gonzalez, JM; Quilez, MRB; Sabin-Muñoz, J; Sánchez-López, AJ; Calatayud, GL; Calles, C; Sempere, AP; Garces, M; Carmona, O; Moral, E; Hervas, JV; Blanco, Y; Sola-Valls, N; Lara, NT; Forero, L; Brieva, L

    Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study

    Journal of Clinical Medicine 12 -. .

    [doi:10.3390/jcm12237243]

  • Mingot, CG; Lasaosa, SS; Campas, LC; Canaval, LC; Sánchez, AG; Ruiz, LB; Alonso, MCM; Moncusi, SP; Marsal, JV; Carner, SC; García, FP

    Prophylactic treatment can modify vascular risk biomarkers in high-frequency episodic and chronic migraine patients: a pilot study

    SCIENTIFIC REPORTS 13 19416-19416. .

    [doi:10.1038/s41598-023-44522-8]

  • Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L

    A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.

    JOURNAL OF NEUROLOGY 270 1-12. .

    [doi:10.1007/s00415-023-11575-8]

  • Sancho-Saldana, A; Gil Sánchez A; Quirant-Sanchez, B; Nogueras, L; Peralta, S; Solana, MJ; Gonzalez-Mingot, C; Gallego, Y; Quibus, L; Ramo-Tello, C; Presas-Rodriguez, S; Martinez-Caceres, E; Torres, P; Hervas, JV; Valls, J; Brieva, L

    Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies.

    Journal of Clinical Medicine 11 -. .

    [doi:10.3390/jcm11092509]

  • Gonzalo, H; Nogueras, L; Gil-Sanchez, A; Hervas, JV; Valcheva, P; Gonzalez-Mingot, C; Martin-Gari, M; Canudes, M; Peralta, S; Solana, MJ; Pamplona, R; Portero-Otin, M; Boada, J; Serrano JCE; Brieva, L

    Impairment of Mitochondrial Redox Status in Peripheral Lymphocytes of Multiple Sclerosis Patients

    Frontiers in Neuroscience 13 938-938. .

    [doi:10.3389/fnins.2019.00938]

  • Nogueras, L; Gonzalo, H; Jove, M; Sol, J; Gil-Sanchez, A; Hervas, JV; Valcheva, P; Gonzalez-Mingot, C; Solana, MJ; Peralta, S; Pamplona, R; Brieva, L

    Lipid profile of cerebrospinal fluid in multiple sclerosis patients: a potential tool for diagnosis

    SCIENTIFIC REPORTS 9 11313-11313. .

    [doi:10.1038/s41598-019-47906-x]

  • Gil, A; Pardinas, B; Hervas, V; Lecina, J; Solana, MJ; Peralta, S; Forne, C; Gonzalez, C; Gonzalo, H; Nogueras, L; Brieva, L

    Pilot Study of Telemedicine in multiple sclerosis to evaluate the effectiveness of a telecommunication system for the detection of the clinical activity of the disease in the number of relapses with respect to the standard clinical practice. TELEM

    MULTIPLE SCLEROSIS JOURNAL 24 795-796. .

  • Nogueras Penabad, L.; Gil Sanchez, A.; Hervas, J. V.; Gonzalez, C.; Marti, M.; Canudes, M.; Peralta, S.; Moga, M. J.; Boada, J.; Pamplona, R.; Portero, M.; Brieva, L.; Gonzalo, H.

    Mitochondrial dysfunction in peripheral blood mononuclear cells from multiple sclerosis patients

    MULTIPLE SCLEROSIS JOURNAL 23 509-509. .

  • Gonzalez-Mingot, C; Sanchez-Monge, IR; Purroy, F; Solana-Moga, MJ; Peralta-Moncusi, S; Lazo-Latorre, C; Gil-Villar, MP; Brieva, L

    Environmental-analytical risk factors influence on the phenotype of amyotrophic lateral sclerosis in a rural setting

    REVISTA DE NEUROLOGIA 65 203-208. .

    [doi:10.33588/rn.6505.2017091]

  • Gonzalo, Hugo; Brieva, Luis; Tatzber, Franz; Jove, Mariona; Cacabelos, Daniel; Cassanye, Anna; Lanau-Angulo, Lucia; Boada, Jordi; Serrano, Jose C. E.; Gonzalez, Cristina; Hernandez, Lourdes; Peralta, Silvia; Pamplona, Reinald; Portero-Otin, Manuel

    Lipidome analysis in multiple sclerosis reveals protein lipoxidative damage as a potential pathogenic mechanism

    JOURNAL OF NEUROCHEMISTRY 123 622-634. .

    [doi:10.1111/j.1471-4159.2012.07934.x]

Proyectos

  • "Registro de pacientes con esclerosis múltiple (EM) tratados con Natalizumab en España"